DANCR and prostate carcinoma: DANCR is shown to be upregulated in gastric cancer, lung cancer, glioma, colorectal cancer, retinoblastoma, osteosarcoma, oesophageal cancer, breast cancer, prostate cancer, and hepatocellular carcinoma [30–37].